
Merck & (MRK) Stock
Merck & Chart
Company Profile
Price: $88.20
Market Cap: $223.11B
Exchange: NYSE
CEO: Mr. Robert M. Davis J.D.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 70.00K
Headquarters: Kenilworth, NJ
Website: Merck &
Business Summary
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Merck & News
Merck & Co., Inc. (MRK) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck & Co., Inc. ("Merck & Co.") (NYSE:MRK) concerning possible violations of federal securities laws. On February 4, 2025, before the market opened, Merck issued a press release announcing their fourth-quarter and full-year 2024 results.

Investors who lost money on Merck & Co., Inc. should contact Levi & Korsinsky about an ongoing investigation - MRK
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck & Co., Inc. ("Merck & Co.") (NYSE:MRK) concerning possible violations of federal securities laws. On February 4, 2025, before the market opened, Merck issued a press release announcing their fourth-quarter and full-year 2024 results.

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin and prednisone (R-CHP) compared to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) alone, for the treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Merck: Don't Fight The Tape, How Low Can It Go?
Despite Merck & Co., Inc.'s strong fundamentals and promising pipeline, current negative sentiment suggests avoiding the stock until it stabilizes and shows signs of recovery. Merck's stock is undervalued but could face further declines, with potential prices dropping to $80, $70, or even $60. The stock market's irrationality can outlast your solvency; avoid the pain of catching a falling knife by waiting for a confirmed bottom in MRK stock.

Should You Pick MRK Stock At $90?
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per share, compared to the consensus estimates of $15.5 billion and $1.62, respectively.

Merck & Co., Inc. (MRK) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck & Co., Inc. ("Merck & Co.") (NYSE:MRK) concerning possible violations of federal securities laws. On February 4, 2025, before the market opened, Merck issued a press release announcing their fourth-quarter and full-year 2024 results.

Merck: Ideal Case Of Why I Love Option Collars (Upgrade To Buy)
Merck's current high-risk profile led me to initially rate it a strong sell, but recent technical indicators suggested a potential bottom near $100. I've upgraded MRK to a buy, using a "Dog Collar" strategy: buying a put option and selling a call option to limit risk. This approach offers controlled outcomes, with $18 upside and $7 downside risk, ensuring I manage risk while seeking potential gains.

Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
Healthcare costs are rising, with PwC projecting the highest commercial healthcare spending growth in 13 years, impacting consumers and insurance companies negatively. Healthcare stocks, including Merck & Co., Inc., have underperformed the S&P 500, making them attractive as the broader market reaches high valuations. Despite Merck's recent 30% stock decline due to poor guidance and Gardasil challenges, I believe it offers good long-term value.

Merck & Co., Inc. (MRK) Q4 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK ) Q4 2024 Results Conference Call February 4, 2025 9:00 AM ET Company Participants Peter Dannenbaum - Senior Vice President, Investor Relations Rob Davis - Chairman and Chief Executive Officer Caroline Litchfield - Chief Financial Officer Dr. Dean Li - President of Merck Research Labs Conference Call Participants Umer Raffat - Evercore ISI Terence Flynn - Morgan Stanley Luisa Hector - Berenberg Mohit Bansal - Wells Fargo Daina Graybosch - Leerink Partners Geoff Meacham - Citi Chris Schott - JPMorgan Tim Anderson - Bank of America Akash Tewari - Jefferies Trung Huynh - UBS Vamil Divan - Guggenheim Courtney Breen - Bernstein James Shin - Deutsche Bank Operator Thank you for standing by. Welcome to the Merck & Company Q4 Sales and Earnings Conference Call.

Merck shares plunge on weak 2025 outlook, pause in Gardasil shipments to China
Merck & Co Inc (NYSE:MRK, ETR:6MK) shares fell more than 10% after the drugmaker issued weak guidance for 2025 and announced it would halt shipments of its HPV vaccine Gardasil to China until at least the middle of the year due to declining demand. It reported a 17% year-over-year decline in Gardasil sales to $1.55 billion for the fourth quarter.

Merck (MRK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook
On Tuesday, Merck & Co Inc MRK reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, sales increased 9%.

Merck's 2025 revenue outlook falls short as it pauses Gardasil vaccine shipments to China
Merck on issued full-year 2025 revenue guidance that fell short of Wall Street's expectations. The company said that sales range reflects a decision to halt shipments of Gardasil, a vaccine that prevents cancer from HPV, into China beginning in February through and going through at least mid-2025.

Merck pauses Gardasil shipments to China, hitting its 2025 outlook
Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong fourth-quarter profit on sales of cancer drug Keytruda.

Merck & Earnings
This section highlights Merck & 's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|---|---|---|---|---|
Read Transcript | Q4 | 2024 | 2025-02-04 | $1.85 | $1.72 |
Read Transcript | Q3 | 2024 | 2024-10-31 | $1.50 | $1.57 |
Read Transcript | Q2 | 2024 | 2024-07-30 | $2.15 | $2.28 |
Read Transcript | Q1 | 2024 | 2024-04-25 | $1.88 | $2.07 |
Read Transcript | Q4 | 2023 | 2024-02-01 | $-0.09 | $0.03 |
Read Transcript | Q3 | 2023 | 2023-10-26 | $1.95 | $2.13 |
Read Transcript | Q2 | 2023 | 2023-08-01 | $-2.17 | $-2.06 |
Read Transcript | Q1 | 2023 | 2023-04-27 | $1.32 | $1.40 |
Financial Statements
Access annual & quarterly financial statements for Merck & , including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Revenue | $60.12B | $59.28B | $48.70B | $41.52B | $46.84B |
Cost of Revenue | $16.13B | $17.41B | $13.63B | $13.62B | $14.11B |
Gross Profit | $43.99B | $41.87B | $35.08B | $27.90B | $32.73B |
Gross Profit Ratio | 73.17% | 70.63% | 72.02% | 67.20% | 69.87% |
Research and Development Expenses | $30.53B | $13.55B | $12.24B | $13.40B | $9.87B |
General and Administrative Expenses | $8.20B | $7.84B | $7.63B | $7.16B | $8.71B |
Selling and Marketing Expenses | $2.30B | $2.20B | $2.00B | $1.80B | $1.90B |
Selling General and Administrative Expenses | $10.50B | $10.04B | $9.63B | $8.96B | $10.62B |
Other Expenses | $- | $960.00M | $468.00M | $469.00M | $-139.00M |
Operating Expenses | $40.91B | $23.59B | $21.88B | $22.35B | $20.49B |
Cost and Expenses | $57.16B | $41.00B | $35.51B | $35.97B | $34.60B |
Interest Income | $365.00M | $157.00M | $36.00M | $59.00M | $274.00M |
Interest Expense | $1.15B | $962.00M | $806.00M | $831.00M | $893.00M |
Depreciation and Amortization | $3.87B | $3.91B | $3.21B | $3.49B | $3.65B |
EBITDA | $6.91B | $21.32B | $17.90B | $10.18B | $16.01B |
EBITDA Ratio | 11.49% | 39.32% | 34.73% | 23.03% | 27.50% |
Operating Income | $2.95B | $19.40B | $13.70B | $6.08B | $9.23B |
Operating Income Ratio | 4.91% | 32.72% | 28.14% | 14.63% | 19.70% |
Total Other Income Expenses Net | $-1.06B | $-1.84B | $680.00M | $315.00M | $3.54B |
Income Before Tax | $1.89B | $16.44B | $13.88B | $8.79B | $11.46B |
Income Before Tax Ratio | 3.14% | 27.74% | 28.50% | 21.17% | 24.47% |
Income Tax Expense | $1.51B | $1.92B | $1.52B | $1.71B | $1.69B |
Net Income | $365.00M | $14.52B | $13.05B | $7.07B | $9.84B |
Net Income Ratio | 0.61% | 24.49% | 26.79% | 17.02% | 21.01% |
EPS | $0.14 | $5.73 | $5.16 | $2.79 | $3.84 |
EPS Diluted | $0.14 | $5.71 | $5.14 | $2.78 | $3.82 |
Weighted Average Shares Outstanding | 2.61B | 2.53B | 2.53B | 2.53B | 2.56B |
Weighted Average Shares Outstanding Diluted | 2.55B | 2.54B | 2.54B | 2.54B | 2.58B |
SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $16.66B | $16.16B | $15.78B | $14.63B | $15.96B | $15.04B | $14.49B | $13.83B | $14.96B | $14.59B | $15.90B | $13.52B | $13.15B | $11.40B | $10.63B | $12.52B | $10.93B | $9.35B | $12.06B | $11.87B |
Cost of Revenue | $4.08B | $4.29B | $3.54B | $3.91B | $4.26B | $4.02B | $3.93B | $3.88B | $3.93B | $4.22B | $5.38B | $3.87B | $3.45B | $3.10B | $3.20B | $5.53B | $3.01B | $2.75B | $3.31B | $3.67B |
Gross Profit | $12.58B | $11.86B | $12.23B | $10.72B | $11.70B | $11.01B | $10.56B | $9.95B | $11.03B | $10.38B | $10.52B | $9.65B | $9.70B | $8.30B | $7.43B | $6.98B | $7.92B | $6.61B | $8.74B | $8.20B |
Gross Profit Ratio | 75.51% | 73.43% | 77.56% | 73.26% | 73.29% | 73.24% | 72.90% | 71.94% | 73.70% | 71.11% | 66.17% | 71.35% | 73.77% | 72.78% | 69.90% | 55.79% | 72.43% | 70.63% | 72.53% | 69.08% |
Research and Development Expenses | $5.86B | $2.89B | $3.99B | $9.63B | $3.31B | $13.32B | $4.28B | $3.77B | $4.40B | $2.80B | $2.58B | $3.07B | $2.44B | $4.32B | $2.41B | $5.84B | $3.35B | $2.08B | $2.21B | $2.55B |
General and Administrative Expenses | $- | $- | $- | $504.00M | $- | $- | $- | $487.00M | $- | $- | $- | $830.00M | $- | $- | $- | $1.28B | $- | $- | $- | $789.00M |
Selling and Marketing Expenses | $- | $- | $- | $2.30B | $- | $- | $- | $2.20B | $- | $- | $- | $2.00B | $- | $- | $- | $1.80B | $- | $- | $- | $2.10B |
Selling General and Administrative Expenses | $2.73B | $2.71B | $2.48B | $2.80B | $2.52B | $2.70B | $2.48B | $2.69B | $2.52B | $2.51B | $2.32B | $2.83B | $2.34B | $2.28B | $2.19B | $3.08B | $2.06B | $2.08B | $2.56B | $2.89B |
Other Expenses | $- | $203.00M | $203.00M | $224.00M | $236.00M | $233.00M | $-348.00M | $290.00M | $242.00M | $157.00M | $275.00M | $224.00M | $2.00M | $130.00M | $111.00M | $134.00M | $156.00M | $55.00M | $118.00M | $294.00M |
Operating Expenses | $8.49B | $5.59B | $6.47B | $12.43B | $5.83B | $16.02B | $6.75B | $6.46B | $6.92B | $5.31B | $4.90B | $5.90B | $4.78B | $6.60B | $4.60B | $8.92B | $5.41B | $4.17B | $4.76B | $5.44B |
Cost and Expenses | $12.67B | $9.89B | $10.02B | $16.34B | $10.09B | $20.05B | $10.68B | $10.34B | $10.85B | $9.53B | $10.28B | $9.77B | $8.23B | $9.71B | $7.80B | $14.46B | $8.42B | $6.92B | $8.08B | $9.11B |
Interest Income | $127.00M | $69.00M | $73.00M | $70.00M | $73.00M | $109.00M | $112.00M | $95.00M | $40.00M | $15.00M | $7.00M | $9.00M | $7.00M | $9.00M | $11.00M | $11.00M | $9.00M | $14.00M | $25.00M | $49.00M |
Interest Expense | $330.00M | $310.00M | $303.00M | $310.00M | $317.00M | $277.00M | $242.00M | $235.00M | $244.00M | $240.00M | $243.00M | $209.00M | $196.00M | $202.00M | $200.00M | $207.00M | $203.00M | $209.00M | $212.00M | $219.00M |
Depreciation and Amortization | $1.19B | $1.06B | $984.00M | $964.00M | $1.01B | $903.00M | $991.00M | $892.00M | $959.00M | $938.00M | $1.12B | $835.00M | $759.00M | $728.00M | $892.00M | $904.00M | $807.00M | $975.00M | $821.00M | $936.00M |
EBITDA | $5.61B | $7.38B | $6.96B | $-772.00M | $7.20B | $-4.16B | $4.88B | $4.64B | $4.79B | $5.67B | $6.22B | $4.95B | $6.22B | $2.61B | $3.84B | $-881.00M | $3.72B | $3.48B | $4.87B | $3.95B |
EBITDA Ratio | 33.66% | 45.39% | 44.50% | -3.11% | 45.08% | -25.05% | 31.48% | 34.45% | 35.74% | 42.33% | 44.17% | 35.63% | 43.26% | 22.48% | 36.16% | -7.12% | 31.83% | 37.21% | 41.01% | 34.05% |
Operating Income | $3.98B | $6.27B | $6.04B | $-1.42B | $6.18B | $-4.67B | $3.57B | $3.87B | $4.39B | $5.24B | $5.90B | $3.98B | $4.93B | $1.83B | $2.95B | $-1.79B | $2.67B | $2.50B | $4.12B | $3.10B |
Operating Income Ratio | 23.92% | 38.80% | 38.26% | -9.70% | 38.72% | -31.06% | 24.64% | 28.00% | 29.33% | 35.90% | 37.13% | 29.45% | 37.49% | 16.09% | 27.77% | -14.34% | 24.45% | 26.78% | 34.20% | 26.16% |
Total Other Income Expenses Net | $106.00M | $-263.00M | $-90.00M | $-627.00M | $-252.00M | $-323.00M | $-156.00M | $26.00M | $-523.00M | $-580.00M | $-761.00M | $160.00M | $343.00M | $21.00M | $150.00M | $-198.00M | $198.00M | $307.00M | $-143.00M | $-313.00M |
Income Before Tax | $4.09B | $6.01B | $5.67B | $-2.05B | $5.62B | $-5.33B | $3.65B | $3.51B | $3.58B | $4.49B | $4.86B | $3.91B | $5.27B | $1.72B | $3.46B | $-1.99B | $3.43B | $3.52B | $3.84B | $2.79B |
Income Before Tax Ratio | 24.55% | 37.18% | 35.94% | -13.98% | 35.21% | -35.48% | 25.20% | 25.40% | 23.95% | 30.75% | 30.57% | 28.91% | 40.03% | 15.06% | 32.58% | -15.92% | 31.37% | 37.62% | 31.83% | 23.53% |
Income Tax Expense | $929.00M | $545.00M | $903.00M | $-821.00M | $870.00M | $637.00M | $825.00M | $495.00M | $330.00M | $538.00M | $554.00M | $85.00M | $695.00M | $503.00M | $276.00M | $99.00M | $483.00M | $509.00M | $619.00M | $428.00M |
Net Income | $3.16B | $5.46B | $4.76B | $-1.23B | $4.75B | $-5.97B | $2.82B | $3.02B | $3.25B | $3.94B | $4.31B | $3.76B | $4.57B | $1.54B | $3.18B | $-2.09B | $2.94B | $3.00B | $3.22B | $2.36B |
Net Income Ratio | 18.95% | 33.76% | 30.19% | -8.38% | 29.73% | -39.74% | 19.47% | 21.81% | 21.71% | 27.03% | 27.11% | 27.79% | 34.72% | 13.55% | 29.91% | -16.73% | 26.91% | 32.10% | 26.70% | 19.85% |
EPS | $1.25 | $2.15 | $1.88 | $-0.48 | $1.87 | $-2.35 | $1.11 | $1.19 | $1.28 | $1.56 | $1.70 | $1.49 | $1.81 | $0.61 | $1.26 | $-0.83 | $1.16 | $1.19 | $1.28 | $0.93 |
EPS Diluted | $1.24 | $2.14 | $1.87 | $-0.48 | $1.86 | $-2.35 | $1.11 | $1.18 | $1.28 | $1.55 | $1.70 | $1.48 | $1.80 | $0.61 | $1.25 | $-0.82 | $1.16 | $1.18 | $1.26 | $0.92 |
Weighted Average Shares Outstanding | 2.53B | 2.53B | 2.53B | 2.55B | 2.54B | 2.54B | 2.54B | 2.54B | 2.53B | 2.53B | 2.53B | 2.53B | 2.53B | 2.53B | 2.53B | 2.53B | 2.53B | 2.53B | 2.52B | 2.54B |
Weighted Average Shares Outstanding Diluted | 2.54B | 2.54B | 2.54B | 2.55B | 2.55B | 2.54B | 2.55B | 2.55B | 2.54B | 2.54B | 2.54B | 2.54B | 2.54B | 2.54B | 2.54B | 2.54B | 2.54B | 2.54B | 2.55B | 2.56B |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Cash and Cash Equivalents | $6.84B | $12.69B | $8.10B | $8.06B | $9.68B |
Short Term Investments | $252.00M | $498.00M | $- | $1.00M | $774.00M |
Cash and Short Term Investments | $7.09B | $13.19B | $8.10B | $8.06B | $10.45B |
Net Receivables | $10.35B | $9.45B | $9.23B | $7.24B | $6.78B |
Inventory | $6.36B | $5.91B | $5.95B | $6.31B | $5.98B |
Other Current Assets | $8.37B | $7.17B | $6.99B | $6.92B | $4.28B |
Total Current Assets | $32.17B | $35.72B | $30.27B | $27.76B | $27.48B |
Property Plant Equipment Net | $24.49B | $21.42B | $19.28B | $17.99B | $15.05B |
Goodwill | $21.20B | $21.20B | $21.26B | $20.24B | $19.43B |
Intangible Assets | $18.01B | $20.27B | $22.93B | $14.60B | $14.20B |
Goodwill and Intangible Assets | $39.21B | $41.47B | $44.20B | $34.84B | $33.62B |
Long Term Investments | $252.00M | $1.01B | $370.00M | $785.00M | $1.47B |
Tax Assets | $1.31B | $1.79B | $3.44B | $1.01B | $1.47B |
Other Non-Current Assets | $10.56B | $7.73B | $8.14B | $9.20B | $5.30B |
Total Non-Current Assets | $74.51B | $73.44B | $75.43B | $63.82B | $56.91B |
Other Assets | $- | $- | $- | $- | $- |
Total Assets | $106.67B | $109.16B | $105.69B | $91.59B | $84.40B |
Account Payables | $3.92B | $4.26B | $4.61B | $4.33B | $3.74B |
Short Term Debt | $1.66B | $1.95B | $2.41B | $6.72B | $3.61B |
Tax Payables | $2.65B | $1.99B | $1.22B | $1.57B | $736.00M |
Deferred Revenue | $- | $- | $- | $- | $- |
Other Current Liabilities | $17.47B | $16.04B | $15.63B | $14.70B | $14.14B |
Total Current Liabilities | $25.69B | $24.24B | $23.87B | $27.33B | $22.22B |
Long Term Debt | $34.61B | $29.76B | $31.91B | $26.70B | $23.50B |
Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $871.00M | $1.79B | $3.44B | $1.01B | $1.47B |
Other Non-Current Liabilities | $7.86B | $7.31B | $8.21B | $11.16B | $11.20B |
Total Non-Current Liabilities | $43.35B | $38.86B | $43.56B | $38.86B | $36.18B |
Other Liabilities | $- | $- | $- | $- | $- |
Total Liabilities | $69.04B | $63.10B | $67.44B | $66.18B | $58.40B |
Preferred Stock | $- | $- | $- | $- | $- |
Common Stock | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B |
Retained Earnings | $53.90B | $61.08B | $53.70B | $47.36B | $46.60B |
Accumulated Other Comprehensive Income Loss | $-5.16B | $-4.77B | $-4.43B | $-6.63B | $-6.19B |
Other Total Stockholders Equity | $-12.94B | $-12.11B | $-12.87B | $-17.20B | $-16.29B |
Total Stockholders Equity | $37.58B | $45.99B | $38.18B | $25.32B | $25.91B |
Total Equity | $37.63B | $46.06B | $38.26B | $25.40B | $26.00B |
Total Liabilities and Stockholders Equity | $106.67B | $109.16B | $105.69B | $91.59B | $84.40B |
Minority Interest | $54.00M | $67.00M | $73.00M | $87.00M | $94.00M |
Total Liabilities and Total Equity | $106.67B | $109.16B | $105.69B | $91.59B | $84.40B |
Total Investments | $1.84B | $1.51B | $370.00M | $785.00M | $2.24B |
Total Debt | $36.27B | $30.69B | $33.10B | $31.79B | $26.35B |
Net Debt | $29.43B | $18.00B | $25.01B | $23.73B | $16.67B |
Balance Sheet Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $14.59B | $11.35B | $5.67B | $6.91B | $8.64B | $5.70B | $9.74B | $12.69B | $11.14B | $9.68B | $8.56B | $8.10B | $10.02B | $8.57B | $6.98B | $8.06B | $7.36B | $11.10B | $7.42B | $9.68B |
Short Term Investments | $- | $50.00M | $40.00M | $252.00M | $168.00M | $718.00M | $680.00M | $498.00M | $103.00M | $453.00M | $372.00M | $- | $26.00M | $12.00M | $16.00M | $785.00M | $6.00M | $10.00M | $7.00M | $774.00M |
Cash and Short Term Investments | $14.59B | $11.40B | $5.71B | $7.16B | $8.81B | $6.42B | $10.42B | $13.19B | $11.25B | $10.13B | $8.93B | $8.10B | $10.02B | $8.57B | $6.98B | $8.06B | $7.36B | $11.10B | $7.43B | $10.45B |
Net Receivables | $11.38B | $11.64B | $12.57B | $11.70B | $11.67B | $12.29B | $11.58B | $9.45B | $9.48B | $9.64B | $9.83B | $9.23B | $8.57B | $7.84B | $8.23B | $7.85B | $8.42B | $7.58B | $8.18B | $6.78B |
Inventory | $6.24B | $6.47B | $6.51B | $6.36B | $6.13B | $5.93B | $5.86B | $5.91B | $5.61B | $5.54B | $5.77B | $5.95B | $7.98B | $7.91B | $8.58B | $6.31B | $8.21B | $7.98B | $7.48B | $5.98B |
Other Current Assets | $8.14B | $8.74B | $6.74B | $7.01B | $5.38B | $5.38B | $5.58B | $7.17B | $7.22B | $6.81B | $6.65B | $6.99B | $6.87B | $6.75B | $5.29B | $5.54B | $4.67B | $4.61B | $4.71B | $4.28B |
Total Current Assets | $40.36B | $38.20B | $31.45B | $32.17B | $31.95B | $29.98B | $33.40B | $35.72B | $33.56B | $32.12B | $31.18B | $30.27B | $31.06B | $28.66B | $26.91B | $27.76B | $26.58B | $29.34B | $26.17B | $27.48B |
Property Plant Equipment Net | $23.45B | $23.22B | $23.05B | $24.49B | $22.53B | $22.23B | $21.76B | $21.42B | $20.42B | $20.06B | $19.75B | $19.28B | $18.57B | $18.06B | $18.30B | $17.99B | $16.92B | $15.79B | $15.27B | $15.05B |
Goodwill | $21.70B | $21.16B | $21.18B | $21.20B | $21.18B | $21.20B | $21.21B | $21.20B | $21.16B | $21.21B | $21.26B | $21.26B | $18.86B | $18.87B | $20.21B | $20.24B | $20.25B | $20.07B | $19.77B | $19.43B |
Intangible Assets | $17.01B | $16.98B | $17.57B | $18.01B | $19.20B | $19.66B | $19.86B | $20.27B | $21.37B | $22.50B | $23.02B | $22.93B | $13.38B | $13.62B | $14.40B | $14.60B | $16.68B | $16.57B | $16.10B | $14.20B |
Goodwill and Intangible Assets | $38.71B | $38.15B | $38.75B | $39.21B | $40.38B | $40.86B | $41.07B | $41.47B | $42.53B | $43.71B | $44.28B | $44.20B | $32.25B | $32.49B | $34.61B | $34.84B | $36.92B | $36.63B | $35.86B | $33.62B |
Long Term Investments | $575.00M | $1.65B | $1.59B | $1.58B | $2.69B | $2.83B | $2.99B | $1.01B | $984.00M | $238.00M | $316.00M | $370.00M | $435.00M | $411.00M | $544.00M | $785.00M | $1.37B | $1.25B | $555.00M | $1.47B |
Tax Assets | $- | $876.00M | $922.00M | $- | $1.02B | $996.00M | $- | $1.79B | $2.42B | $2.97B | $3.07B | $3.44B | $1.53B | $1.49B | $1.20B | $1.01B | $1.78B | $2.09B | $1.94B | $1.47B |
Other Non-Current Assets | $864.00M | $10.53B | $10.10B | $9.23B | $8.16B | $7.58B | $8.58B | $7.73B | $7.17B | $8.00B | $8.07B | $8.14B | $9.66B | $9.56B | $9.28B | $9.20B | $6.23B | $5.51B | $5.11B | $5.30B |
Total Non-Current Assets | $63.59B | $74.42B | $74.40B | $74.51B | $74.77B | $74.49B | $74.39B | $73.44B | $73.52B | $74.98B | $75.48B | $75.43B | $62.44B | $62.02B | $63.94B | $63.82B | $63.22B | $61.27B | $58.74B | $56.91B |
Other Assets | $13.58B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Assets | $117.53B | $112.63B | $105.85B | $106.67B | $106.73B | $104.47B | $107.80B | $109.16B | $107.08B | $107.09B | $106.67B | $105.69B | $93.49B | $90.69B | $90.85B | $91.59B | $89.80B | $90.61B | $84.91B | $84.40B |
Account Payables | $3.59B | $3.52B | $3.51B | $3.92B | $3.51B | $3.44B | $3.68B | $4.26B | $3.37B | $3.48B | $3.71B | $4.61B | $3.37B | $3.90B | $4.03B | $4.59B | $3.74B | $3.45B | $3.57B | $3.74B |
Short Term Debt | $3.15B | $3.07B | $3.08B | $1.66B | $887.00M | $2.84B | $2.67B | $1.95B | $1.94B | $2.98B | $1.21B | $2.41B | $3.53B | $2.49B | $7.25B | $6.72B | $2.42B | $4.72B | $6.36B | $3.61B |
Tax Payables | $4.33B | $2.78B | $2.40B | $2.65B | $1.98B | $1.49B | $1.87B | $1.99B | $1.70B | $1.44B | $1.57B | $1.22B | $954.00M | $971.00M | $1.49B | $1.57B | $984.00M | $1.27B | $1.03B | $736.00M |
Deferred Revenue | $- | $2.78B | $2.40B | $4.63B | $3.86B | $3.37B | $3.78B | $- | $2.42B | $2.97B | $- | $- | $954.00M | $971.00M | $1.49B | $1.01B | $- | $- | $- | $- |
Other Current Liabilities | $18.52B | $16.69B | $16.11B | $17.47B | $16.72B | $15.62B | $14.91B | $16.04B | $15.99B | $15.27B | $15.82B | $15.63B | $15.87B | $14.55B | $13.59B | $14.44B | $13.26B | $12.75B | $12.52B | $14.14B |
Total Current Liabilities | $29.59B | $26.06B | $25.10B | $25.69B | $23.09B | $23.39B | $23.13B | $24.24B | $23.00B | $23.17B | $22.32B | $23.87B | $23.73B | $21.91B | $26.36B | $27.33B | $20.41B | $22.18B | $23.48B | $22.22B |
Long Term Debt | $34.98B | $34.72B | $31.14B | $34.61B | $33.97B | $34.07B | $28.07B | $29.76B | $28.48B | $28.68B | $30.59B | $31.91B | $22.91B | $24.03B | $24.00B | $26.72B | $26.32B | $26.16B | $21.64B | $23.50B |
Deferred Revenue Non-Current | $- | $- | $- | $928.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $876.00M | $922.00M | $871.00M | $1.02B | $996.00M | $1.44B | $1.79B | $2.42B | $2.97B | $3.07B | $3.44B | $1.53B | $1.49B | $1.20B | $1.01B | $1.78B | $2.09B | $1.94B | $1.47B |
Other Non-Current Liabilities | $- | $7.33B | $8.26B | $7.86B | $7.34B | $7.26B | $8.24B | $7.31B | $8.66B | $8.95B | $9.74B | $8.21B | $9.47B | $9.87B | $12.24B | $11.12B | $12.03B | $12.45B | $11.55B | $11.20B |
Total Non-Current Liabilities | $34.98B | $42.92B | $40.33B | $43.35B | $42.33B | $42.33B | $37.76B | $38.86B | $39.56B | $40.61B | $43.40B | $43.56B | $33.90B | $35.39B | $37.45B | $38.86B | $40.12B | $40.69B | $35.13B | $36.18B |
Other Liabilities | $8.40B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities | $72.97B | $68.98B | $65.42B | $69.04B | $65.43B | $65.73B | $60.89B | $63.10B | $62.56B | $63.78B | $65.72B | $67.44B | $57.63B | $57.30B | $63.81B | $66.18B | $60.53B | $62.87B | $58.61B | $58.40B |
Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B |
Retained Earnings | $61.38B | $60.19B | $56.70B | $53.90B | $57.08B | $54.20B | $62.04B | $61.08B | $59.93B | $58.44B | $56.25B | $53.70B | $51.69B | $48.78B | $48.89B | $47.36B | $51.11B | $49.72B | $48.27B | $46.60B |
Accumulated Other Comprehensive Income Loss | $-5.37B | $-5.36B | $-5.27B | $-5.16B | $-4.92B | $-4.90B | $-4.88B | $-4.77B | $-4.74B | $-4.33B | $-4.37B | $-4.43B | $-4.59B | $-4.63B | $-6.62B | $-6.63B | $-6.38B | $-6.39B | $-6.39B | $-6.19B |
Other Total Stockholders Equity | $-13.30B | $-13.03B | $-12.85B | $-12.94B | $-12.71B | $-12.39B | $-12.11B | $-12.11B | $-12.52B | $-12.65B | $-12.79B | $-12.87B | $-13.10B | $-12.64B | $-17.11B | $-17.20B | $-17.33B | $-17.48B | $-17.46B | $-16.29B |
Total Stockholders Equity | $44.50B | $43.58B | $40.36B | $37.58B | $41.25B | $38.69B | $46.83B | $45.99B | $44.46B | $43.24B | $40.88B | $38.18B | $35.79B | $33.29B | $26.95B | $25.32B | $29.19B | $27.64B | $26.20B | $25.91B |
Total Equity | $44.56B | $43.65B | $40.42B | $37.63B | $41.30B | $38.74B | $46.91B | $46.06B | $44.52B | $43.32B | $40.95B | $38.26B | $35.86B | $33.39B | $27.04B | $25.40B | $29.27B | $27.74B | $26.30B | $26.00B |
Total Liabilities and Stockholders Equity | $117.53B | $112.63B | $105.85B | $106.67B | $106.73B | $104.47B | $107.80B | $109.16B | $107.08B | $107.09B | $106.67B | $105.69B | $93.49B | $90.69B | $90.85B | $91.59B | $89.80B | $90.61B | $84.91B | $84.40B |
Minority Interest | $58.00M | $66.00M | $60.00M | $54.00M | $54.00M | $49.00M | $71.00M | $67.00M | $66.00M | $75.00M | $70.00M | $73.00M | $69.00M | $94.00M | $94.00M | $87.00M | $84.00M | $102.00M | $95.00M | $94.00M |
Total Liabilities and Total Equity | $117.53B | $112.63B | $105.85B | $106.67B | $106.73B | $104.47B | $107.80B | $109.16B | $107.08B | $107.09B | $106.67B | $105.69B | $93.49B | $90.69B | $90.85B | $91.59B | $89.80B | $90.61B | $84.91B | $84.40B |
Total Investments | $575.00M | $1.70B | $1.63B | $1.84B | $2.85B | $3.55B | $3.67B | $1.51B | $1.09B | $691.00M | $688.00M | $370.00M | $435.00M | $411.00M | $544.00M | $1.57B | $1.37B | $1.25B | $562.00M | $2.24B |
Total Debt | $38.13B | $37.79B | $34.22B | $36.27B | $34.86B | $36.91B | $30.75B | $30.69B | $30.42B | $31.66B | $31.79B | $33.10B | $26.44B | $26.52B | $31.25B | $31.79B | $28.74B | $30.87B | $28.00B | $26.35B |
Net Debt | $23.54B | $26.44B | $28.55B | $29.36B | $26.21B | $31.21B | $21.01B | $18.00B | $19.27B | $21.99B | $23.24B | $25.01B | $16.43B | $17.95B | $24.27B | $23.73B | $21.39B | $19.77B | $20.57B | $16.67B |
Annual Cash Flow
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Net Income | $365.00M | $14.53B | $12.36B | $7.08B | $9.78B |
Depreciation and Amortization | $3.87B | $3.91B | $3.21B | $3.62B | $3.65B |
Deferred Income Tax | $-1.90B | $-1.57B | $187.00M | $-668.00M | $-556.00M |
Stock Based Compensation | $645.00M | $541.00M | $479.00M | $441.00M | $417.00M |
Change in Working Capital | $-2.21B | $-2.78B | $-3.84B | $-4.59B | $-2.07B |
Accounts Receivables | $-1.15B | $-644.00M | $-2.03B | $-1.00B | $294.00M |
Inventory | $-816.00M | $-161.00M | $-674.00M | $-855.00M | $-508.00M |
Accounts Payables | $-380.00M | $-289.00M | $405.00M | $724.00M | $399.00M |
Other Working Capital | $139.00M | $-1.69B | $-1.54B | $-3.46B | $-2.25B |
Other Non Cash Items | $12.23B | $4.47B | $1.71B | $4.33B | $2.22B |
Net Cash Provided by Operating Activities | $13.01B | $19.09B | $14.11B | $10.25B | $13.44B |
Investments in Property Plant and Equipment | $-3.86B | $-4.39B | $-4.45B | $-4.68B | $-3.47B |
Acquisitions Net | $-12.03B | $-121.00M | $-12.91B | $-6.61B | $-4.95B |
Purchases of Investments | $-955.00M | $-1.20B | $-1.00M | $-1.09B | $-3.20B |
Sales Maturities of Investments | $1.66B | $721.00M | $1.03B | $2.81B | $8.62B |
Other Investing Activities | $1.11B | $32.00M | $-225.00M | $130.00M | $378.00M |
Net Cash Used for Investing Activities | $-14.08B | $-4.96B | $-16.55B | $-9.44B | $-2.63B |
Debt Repayment | $4.18B | $-2.25B | $1.63B | $5.01B | $1.25B |
Common Stock Issued | $- | $384.00M | $- | $- | $- |
Common Stock Repurchased | $-1.35B | $-384.00M | $-840.00M | $-1.28B | $-4.78B |
Dividends Paid | $-7.45B | $-7.01B | $-6.61B | $-6.21B | $-5.70B |
Other Financing Activities | $-203.00M | $144.00M | $8.41B | $-347.00M | $366.00M |
Net Cash Used Provided by Financing Activities | $-4.81B | $-9.12B | $2.59B | $-2.83B | $-8.86B |
Effect of Forex Changes on Cash | $23.00M | $-410.00M | $-133.00M | $253.00M | $17.00M |
Net Change in Cash | $-5.86B | $4.61B | $14.00M | $-1.77B | $1.97B |
Cash at End of Period | $6.91B | $12.77B | $8.17B | $8.16B | $9.93B |
Cash at Beginning of Period | $12.77B | $8.17B | $8.15B | $9.93B | $7.97B |
Operating Cash Flow | $13.01B | $19.09B | $14.11B | $10.25B | $13.44B |
Capital Expenditure | $-3.86B | $-4.39B | $-4.45B | $-4.68B | $-3.47B |
Free Cash Flow | $9.14B | $14.71B | $9.66B | $5.57B | $9.97B |
Cash Flow Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $3.16B | $5.46B | $4.76B | $-1.23B | $4.75B | $-5.97B | $2.82B | $3.02B | $3.25B | $3.95B | $4.31B | $3.82B | $4.57B | $777.00M | $3.19B | $-2.09B | $2.94B | $3.01B | $3.22B | $2.36B |
Depreciation and Amortization | $1.19B | $1.06B | $984.00M | $964.00M | $1.01B | $903.00M | $991.00M | $892.00M | $959.00M | $938.00M | $1.12B | $835.00M | $759.00M | $690.00M | $930.00M | $904.00M | $852.00M | $1.05B | $821.00M | $936.00M |
Deferred Income Tax | $-401.00M | $-181.00M | $-51.00M | $-931.00M | $-336.00M | $-355.00M | $-277.00M | $-307.00M | $-661.00M | $-262.00M | $-338.00M | $159.00M | $-1.00M | $39.00M | $-10.00M | $-715.00M | $-75.00M | $40.00M | $82.00M | $-170.00M |
Stock Based Compensation | $195.00M | $203.00M | $176.00M | $167.00M | $164.00M | $169.00M | $145.00M | $145.00M | $139.00M | $137.00M | $120.00M | $119.00M | $117.00M | $132.00M | $111.00M | $121.00M | $116.00M | $105.00M | $108.00M | $111.00M |
Change in Working Capital | $2.58B | $-1.01B | $-3.38B | $144.00M | $2.18B | $-1.64B | $-2.89B | $-347.00M | $263.00M | $-1.40B | $-1.30B | $-45.00M | $-139.00M | $-1.55B | $-2.10B | $1.05B | $-1.45B | $-527.00M | $-3.67B | $1.40B |
Accounts Receivables | $- | $- | $- | $-1.15B | $- | $- | $- | $-644.00M | $- | $- | $- | $-2.03B | $- | $- | $- | $-1.00B | $- | $- | $- | $294.00M |
Inventory | $- | $- | $- | $-816.00M | $- | $- | $- | $-161.00M | $- | $- | $- | $-674.00M | $- | $- | $- | $-895.00M | $- | $- | $- | $-508.00M |
Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $41.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Working Capital | $2.58B | $-1.01B | $-3.38B | $144.00M | $2.18B | $-1.64B | $-2.89B | $417.00M | $263.00M | $-1.40B | $-1.30B | $2.52B | $-139.00M | $-1.55B | $-2.10B | $1.05B | $-1.45B | $-527.00M | $-3.67B | $1.40B |
Other Non Cash Items | $2.57B | $2.44B | $2.75B | $1.13B | $-47.00M | $10.60B | $549.00M | $1.03B | $1.65B | $939.00M | $851.00M | $139.00M | $-510.00M | $2.41B | $-331.00M | $4.74B | $-228.00M | $-325.00M | $143.00M | $152.00M |
Net Cash Provided by Operating Activities | $9.29B | $5.64B | $3.09B | $246.00M | $7.72B | $3.70B | $1.34B | $4.43B | $5.60B | $4.30B | $4.76B | $5.03B | $4.80B | $2.49B | $1.79B | $4.01B | $2.17B | $3.37B | $707.00M | $4.79B |
Investments in Property Plant and Equipment | $-783.00M | $-791.00M | $-861.00M | $-989.00M | $-902.00M | $-965.00M | $-1.01B | $-1.15B | $-1.13B | $-1.13B | $-984.00M | $-1.21B | $-1.17B | $-934.00M | $-1.13B | $-1.51B | $-1.52B | $-668.00M | $-986.00M | $-1.14B |
Acquisitions Net | $-598.00M | $- | $-746.00M | $- | $902.00M | $-10.71B | $-1.33B | $- | $-121.00M | $- | $- | $-11.26B | $1.00M | $-1.63B | $-14.00M | $-3.15B | $-586.00M | $-321.00M | $-2.54B | $-25.00M |
Purchases of Investments | $-169.00M | $-49.00M | $-15.00M | $-251.00M | $-117.00M | $-25.00M | $-562.00M | $-494.00M | $-5.00M | $-333.00M | $-372.00M | $- | $1.17B | $- | $-1.00M | $-1.02B | $-1.00M | $-28.00M | $-49.00M | $-822.00M |
Sales Maturities of Investments | $50.00M | $60.00M | $260.00M | $169.00M | $704.00M | $285.00M | $500.00M | $12.00M | $335.00M | $373.00M | $1.00M | $529.00M | $111.00M | $- | $386.00M | $918.00M | $2.00M | $76.00M | $1.82B | $1.16B |
Other Investing Activities | $-2.35B | $-289.00M | $-14.00M | $1.12B | $-921.00M | $-33.00M | $37.00M | $-117.00M | $-45.00M | $12.00M | $182.00M | $-106.00M | $-1.17B | $-143.00M | $25.00M | $-11.00M | $-54.00M | $59.00M | $136.00M | $58.00M |
Net Cash Used for Investing Activities | $-3.85B | $-1.07B | $-1.38B | $53.00M | $-334.00M | $-11.44B | $-2.36B | $-1.75B | $-962.00M | $-1.08B | $-1.17B | $-12.05B | $-1.06B | $-2.71B | $-738.00M | $-4.78B | $-2.15B | $-882.00M | $-1.63B | $-763.00M |
Debt Repayment | $-1.00M | $3.60B | $-751.00M | $-3.00M | $-1.95B | $-1.75B | $-1.00M | $-1.00M | $-1.00B | $- | $-1.25B | $6.77B | $- | $- | $-365.00M | $2.86B | $-2.31B | $2.83B | $1.63B | $182.00M |
Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $265.00M | $10.00M | $97.00M | $12.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock Repurchased | $-444.00M | $-251.00M | $-122.00M | $-393.00M | $-466.00M | $-338.00M | $-149.00M | $-265.00M | $-10.00M | $- | $- | $-18.00M | $-583.00M | $-239.00M | $- | $- | $- | $- | $-1.28B | $-1.05B |
Dividends Paid | $-1.95B | $-1.99B | $-1.95B | $-1.85B | $-1.85B | $-1.89B | $-1.85B | $-1.75B | $-1.75B | $-1.77B | $-1.75B | $-1.64B | $-1.65B | $-1.67B | $-1.65B | $-1.54B | $-1.54B | $-1.58B | $-1.55B | $-1.41B |
Other Financing Activities | $-27.00M | $-147.00M | $9.00M | $3.00M | $-3.00M | $7.73B | $-51.00M | $197.00M | $45.00M | $-7.00M | $-91.00M | $101.00M | $-42.00M | $3.67B | $-88.00M | $57.00M | $-28.00M | $-114.00M | $-290.00M | $262.00M |
Net Cash Used Provided by Financing Activities | $-2.42B | $1.22B | $-2.81B | $-2.25B | $-4.27B | $3.76B | $-2.05B | $-1.55B | $-2.70B | $-1.78B | $-3.09B | $5.21B | $-2.27B | $1.76B | $-2.10B | $1.37B | $-3.85B | $1.14B | $-1.49B | $-2.01B |
Effect of Forex Changes on Cash | $294.00M | $-82.00M | $-138.00M | $186.00M | $-157.00M | $-93.00M | $87.00M | $366.00M | $-412.00M | $-309.00M | $-55.00M | $-68.00M | $-46.00M | $78.00M | $-97.00M | $164.00M | $87.00M | $65.00M | $-63.00M | $43.00M |
Net Change in Cash | $3.34B | $5.67B | $-1.24B | $-1.74B | $2.94B | $-4.03B | $-3.04B | $1.49B | $1.53B | $1.14B | $447.00M | $-1.88B | $1.42B | $1.61B | $-1.14B | $764.00M | $-3.75B | $3.69B | $-2.47B | $2.06B |
Cash at End of Period | $14.69B | $11.35B | $5.67B | $6.91B | $8.64B | $5.70B | $9.74B | $12.77B | $11.28B | $9.75B | $8.61B | $8.17B | $10.05B | $8.63B | $7.02B | $8.16B | $7.40B | $11.15B | $7.46B | $9.93B |
Cash at Beginning of Period | $11.35B | $5.67B | $6.91B | $8.64B | $5.70B | $9.74B | $12.77B | $11.28B | $9.75B | $8.61B | $8.17B | $10.05B | $8.63B | $7.02B | $8.16B | $7.40B | $11.15B | $7.46B | $9.93B | $7.87B |
Operating Cash Flow | $9.29B | $5.64B | $3.09B | $246.00M | $7.72B | $3.70B | $1.34B | $4.43B | $5.60B | $4.30B | $4.76B | $5.03B | $4.80B | $2.49B | $1.79B | $4.01B | $2.17B | $3.37B | $707.00M | $4.79B |
Capital Expenditure | $-783.00M | $-791.00M | $-861.00M | $-989.00M | $-902.00M | $-965.00M | $-1.01B | $-1.15B | $-1.13B | $-1.13B | $-984.00M | $-1.21B | $-1.17B | $-934.00M | $-1.13B | $-1.51B | $-1.52B | $-668.00M | $-986.00M | $-1.14B |
Free Cash Flow | $8.51B | $4.85B | $2.23B | $-743.00M | $6.82B | $2.74B | $332.00M | $3.28B | $4.48B | $3.17B | $3.78B | $3.82B | $3.62B | $1.56B | $657.00M | $2.49B | $657.00M | $2.70B | $-279.00M | $3.66B |
Merck & Stock Forecast
Analyst ratings, price targets, and earnings estimates for MRK.
MRK Analyst Ratings
Strong Buy
Based on 24 analysts in the past 3 months
MRK Stock 12 Month Forecast
$121.33
Based on 3 analysts in the last 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
Date | Analyst | Firm | Price Target | Price When Posted | Upside |
---|---|---|---|---|---|
Feb 05, 2025 | Terence Flynn | Morgan Stanley | $106.00 | $90.74 | 16.8% |
Dec 02, 2024 | Courtney Breen | Bernstein | $110.00 | $100.69 | 9.2% |
Nov 15, 2024 | Akash Tewari | Jefferies | $148.00 | $98.36 | 50.5% |
Nov 01, 2024 | Evan David Seigerman | BMO Capital | $136.00 | $101.88 | 33.5% |
Oct 09, 2024 | Trung Huynh | UBS | $136.00 | $108.88 | 24.9% |
Oct 07, 2024 | Carter Gould | Barclays | $140.00 | $109.77 | 27.5% |
Aug 15, 2024 | Akash Tewari | Jefferies | $147.00 | $113.49 | 29.5% |
Jul 31, 2024 | Colin Bristow | UBS | $142.00 | $112.89 | 25.8% |
Jul 31, 2024 | Geoff Meacham | Bank of America Securities | $145.00 | $115.21 | 25.9% |
Jun 12, 2024 | Mohit Bansal | Wells Fargo | $140.00 | $131.05 | 6.8% |
Merck & Dividends
Explore Merck & 's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
2.62%
Dividend Payout Ratio
2039.73%
Dividend Paid & Capex Coverage Ratio
1.15x
Merck & Dividend History
Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|
$0.81 | $0.81 | March 17, 2025 | March 17, 2025 | April 07, 2025 | January 28, 2025 |
$0.81 | $0.81 | December 16, 2024 | December 16, 2024 | January 08, 2025 | November 19, 2024 |
$0.77 | $0.77 | September 16, 2024 | September 16, 2024 | October 07, 2024 | July 23, 2024 |
$0.77 | $0.77 | June 17, 2024 | June 17, 2024 | July 08, 2024 | May 28, 2024 |
$0.77 | $0.77 | March 14, 2024 | March 15, 2024 | April 05, 2024 | January 23, 2024 |
$0.77 | $0.77 | December 14, 2023 | December 15, 2023 | January 08, 2024 | November 28, 2023 |
$0.73 | $0.73 | September 14, 2023 | September 15, 2023 | October 06, 2023 | July 25, 2023 |
$0.73 | $0.73 | June 14, 2023 | June 15, 2023 | July 10, 2023 | May 23, 2023 |
$0.73 | $0.73 | March 14, 2023 | March 15, 2023 | April 10, 2023 | January 24, 2023 |
$0.73 | $0.73 | December 14, 2022 | December 15, 2022 | January 09, 2023 | November 29, 2022 |
$0.69 | $0.69 | September 14, 2022 | September 15, 2022 | October 07, 2022 | July 26, 2022 |
$0.69 | $0.69 | June 14, 2022 | June 15, 2022 | July 08, 2022 | May 24, 2022 |
$0.69 | $0.69 | March 14, 2022 | March 15, 2022 | April 07, 2022 | January 25, 2022 |
$0.69 | $0.69 | December 14, 2021 | December 15, 2021 | January 07, 2022 | November 30, 2021 |
$0.65 | $0.65 | September 14, 2021 | September 15, 2021 | October 07, 2021 | July 27, 2021 |
$0.65 | $0.65 | June 14, 2021 | June 15, 2021 | July 07, 2021 | May 25, 2021 |
$0.65 | $0.62023 | March 12, 2021 | March 15, 2021 | April 07, 2021 | January 26, 2021 |
$0.65 | $0.62023 | December 14, 2020 | December 15, 2020 | January 08, 2021 | November 17, 2020 |
$0.61 | $0.58206 | September 14, 2020 | September 15, 2020 | October 07, 2020 | July 28, 2020 |
$0.61 | $0.58206 | June 12, 2020 | June 15, 2020 | July 07, 2020 | May 26, 2020 |
Peers: Drug Manufacturers - General
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|---|---|---|---|---|
![]() AbbVie Inc.
ABBV
|
$341.08B | $193.01 | $2.75 | $56.34 | $26.45 |
![]() Pfizer Inc.
PFE
|
$145.73B | $25.72 | $0.38 | $76.67 | $1.83 |
![]() Eli Lilly and Company
LLY
|
$835.31B | $879.91 | $5.83 | $100.04 | $48.67 |
![]() Bristol-Myers Squibb Company
BMY
|
$114.90B | $56.65 | $3.88 | $13.23 | $3.61 |
![]() Amgen Inc.
AMGN
|
$158.54B | $294.95 | $7.62 | $34.22 | $0.00 |
![]() Gilead Sciences, Inc.
GILD
|
$121.31B | $97.34 | $4.54 | $17.85 | $4.43 |
![]() Johnson & Johnson
JNJ
|
$371.04B | $154.11 | $13.88 | $11.30 | $5.77 |
Related Metrics
Explore detailed financial metrics and analysis for MRK.